IL327125A - תרכובות פירולו[2,1-f][1,2,4]טריאזין הפועלות כנגד מחלות סרטן, מחלות דלקתיות ומחלות פיברוטיות באמצעות אינטראקציה עם חלבונים ממשפחת-העל RAS - Google Patents
תרכובות פירולו[2,1-f][1,2,4]טריאזין הפועלות כנגד מחלות סרטן, מחלות דלקתיות ומחלות פיברוטיות באמצעות אינטראקציה עם חלבונים ממשפחת-העל RASInfo
- Publication number
- IL327125A IL327125A IL327125A IL32712526A IL327125A IL 327125 A IL327125 A IL 327125A IL 327125 A IL327125 A IL 327125A IL 32712526 A IL32712526 A IL 32712526A IL 327125 A IL327125 A IL 327125A
- Authority
- IL
- Israel
- Prior art keywords
- pyrrolo
- inflammatory diseases
- acting against
- triazine compounds
- fibrotic disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363589174P | 2023-10-10 | 2023-10-10 | |
| PCT/US2024/050482 WO2025080653A1 (en) | 2023-10-10 | 2024-10-09 | Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL327125A true IL327125A (he) | 2026-05-01 |
Family
ID=93257604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL327125A IL327125A (he) | 2023-10-10 | 2024-10-09 | תרכובות פירולו[2,1-f][1,2,4]טריאזין הפועלות כנגד מחלות סרטן, מחלות דלקתיות ומחלות פיברוטיות באמצעות אינטראקציה עם חלבונים ממשפחת-העל RAS |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2024360599A1 (he) |
| IL (1) | IL327125A (he) |
| WO (1) | WO2025080653A1 (he) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EP4504341A1 (en) | 2022-04-08 | 2025-02-12 | Shy Therapeutics LLC | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
-
2024
- 2024-10-09 IL IL327125A patent/IL327125A/he unknown
- 2024-10-09 WO PCT/US2024/050482 patent/WO2025080653A1/en active Pending
- 2024-10-09 AU AU2024360599A patent/AU2024360599A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025080653A1 (en) | 2025-04-17 |
| AU2024360599A1 (en) | 2026-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haskó et al. | An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice | |
| JP2020176144A (ja) | 抗ＴＮＦα糖操作抗体群およびその使用 | |
| DK1414837T3 (da) | Adenosin A3-receptoragonister | |
| DK1265928T3 (da) | RSV-neutraliserende antistoffer med ultra høj affinitet | |
| BR9608625A (pt) | Composto. | |
| ATE163420T1 (de) | C-22 ringstabilisierte rapamycin derivate | |
| AU2002257162A1 (en) | Humanized antibodies | |
| CY1109764T1 (el) | Υποκατεστημενα βενζαζολια και χρηση αυτων ως αναστολεις κινασης raf | |
| WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
| WO2006124354A3 (en) | Tyrosine kinase inhibitors | |
| PL1699459T3 (pl) | Sposób leczenia stwardnienia rozsianego | |
| FI970588L (fi) | Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä | |
| CA3307338A1 (en) | Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins | |
| IL315733A (he) | תרכובות המקיימות אינטראקציה עם חלבוני ras על-משפחתיים לטיפול בסרטן, מחלות דלקתיות, ברסופתיות ומחלות פיברוטיות | |
| MX9201763A (es) | Derivados de pirimidina para aumentar la actividad antitumores. | |
| NO20052579L (no) | Derviater av (6,7-dihydro-5h-imidazo(i,2-a) imidazol-3-sulfonylamino)-pro pionamid | |
| CO5560536A2 (es) | Uso de imidazotriazinonas sustituidas en la posicion 2 con alcoxifenilo | |
| WO2007050380A3 (en) | Tyrosine kinase inhibitors | |
| WO2004022573A3 (en) | Adenosine a3 receptor agonists | |
| EA200901536A1 (ru) | Пиразолопиримидиноновый ингибитор киназ | |
| Kiaie et al. | Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation | |
| CA2107896A1 (en) | Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins | |
| MX383514B (es) | Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa. | |
| NO20020329D0 (no) | Antitumor antistoffer, proteiner og anvendelser derav | |
| Bachet et al. | 532P G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): the GERCOR LONGBOARD study |